Cladribine Tablets: Observational Evaluation of Effectiveness and PROs in Suboptimally Controlled Patients Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
Cladribine Tablets: Observational Evaluation of Effectiveness and PROs in Suboptimally Controlled Patients Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
To evaluate the effectiveness, safety and Patient-Reported Outcomes (PROs) of cladribine tablets in participants with RMS including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS), who transition to cladribine tablets after suboptimal response to any oral or infusion Disease-Modifying Drugs (DMDs) approved in the United States (US) for RMS in a real-world-setting.
Inclusion Criteria:
Exclusion Criteria:
Colorado Springs, Colorado 80907, United States
Orlando, Florida 32806, United States
Detroit, Michigan 48201, United States
Charlotte, North Carolina 28203, United States
Philadelphia, Pennsylvania 19107, United States
McAllen, Texas 78503, United States
Spokane, Washington 99202, United States
Tacoma, Washington 98405, United States
Milwaukee, Wisconsin 53215, United States